In addition, insulin sensitizers (such as metformin, rosiglitazone and pioglitazone) used when appropriate and in patients with mild-to-moderate CKD (within CKD stage 3a, estimated glomerular filtration rate > 45 mL/min/1.73 m2), can be administered in conjunction with other diabetes treatment. The gene discussed is INS; the disease is chronic kidney disease.